Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT01450696
Registration number
NCT01450696
Ethics application status
Date submitted
10/10/2011
Date registered
12/10/2011
Date last updated
28/11/2016
Titles & IDs
Public title
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Query!
Scientific title
A Randomized, Open Label, Multicenter Phase IIIb Study Comparing Two Trastuzumab Dosing Regimens, Each in Combination With Cisplatin/Capecitabine Chemotherapy, as First-Line Therapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Adenocarcinoma Who Have Not Received Prior Treatment for Metastatic Disease
Query!
Secondary ID [1]
0
0
2011-001526-19
Query!
Secondary ID [2]
0
0
BO27798
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
HELOISE
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Gastric Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Stomach
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Capecitabine
Treatment: Drugs - Cisplatin
Treatment: Drugs - Herceptin
Active comparator: Capecitabine + Cisplatin + Herceptin (6 mg/kg) - Participants will receive Herceptin at a loading dose of 8 mg/kg on Day 1 of Cycle 1 followed by 6 mg/kg q3w as a standard of care from Day 1 of Cycle 2 until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason (cycle length = 21 days). Participants will also receive cisplatin 80 mg/m\^2 intravenously q3w plus capecitabine 800 mg/m\^2 orally twice daily for 14 days q3w for up to 6 treatment cycles (Cycles 1 to 6).
Experimental: Capecitabine + Cisplatin + Herceptin (10 mg/kg) - Participants will receive Herceptin at a loading dose of 8 mg/kg on Day 1 of Cycle 1 followed by 10 mg/kg q3w from Day 1 of Cycle 2 until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason (cycle length = 21 days). Participants will also receive cisplatin 80 mg/m\^2 intravenously q3w plus capecitabine 800 mg/m\^2 orally twice daily for 14 days q3w for up to 6 treatment cycles (Cycles 1 to 6).
Treatment: Drugs: Capecitabine
Capecitabine will be administered at a dose of 800 mg/m\^2 orally twice daily for 14 days q3w for up to 6 cycles (Cycles 1 to 6).
Treatment: Drugs: Cisplatin
Cisplatin will be administered at a dose of 80 mg/m\^2 intravenously q3w on Day 1 of each 3-week cycle for up to 6 cycles (Cycles 1 to 6).
Treatment: Drugs: Herceptin
Herceptin will be administered at a loading dose of 8 mg/kg on Day 1 of Cycle 1 followed by 6 or 10 mg/kg (depending upon treatment assignment) q3w from Day 1 of Cycle 2 until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants Who Died - FAS
Query!
Assessment method [1]
0
0
The percentage of participants who died as of the analysis data cutoff date of 13 February 2015 was reported among participants from the FAS with available data.
Query!
Timepoint [1]
0
0
From date of randomization until death or premature withdrawal (up to approximately 31 months or data cutoff date of 13 February 2015)
Query!
Primary outcome [2]
0
0
Overall Survival - FAS
Query!
Assessment method [2]
0
0
Overall survival was defined as the time from the date of randomization to the date of death from any cause. Overall survival was estimated among participants from the FAS using the Kaplan-Meier approach. The 95 percent (%) confidence interval (CI) for median was computed using the method of Brookmeyer and Crowley.
Query!
Timepoint [2]
0
0
From date of randomization until death or premature withdrawal (up to approximately 31 months or data cutoff date of 13 February 2015)
Query!
Secondary outcome [1]
0
0
Percentage of Participants Who Died - Per Protocol Set (PPS)
Query!
Assessment method [1]
0
0
The percentage of participants who died as of the analysis data cutoff date of 13 February 2015 was reported among participants from the PPS.
Query!
Timepoint [1]
0
0
From date of randomization until death or premature withdrawal (up to approximately 31 months or data cutoff date of 13 February 2015)
Query!
Secondary outcome [2]
0
0
Overall Survival - PPS
Query!
Assessment method [2]
0
0
Overall survival was defined as the time from the date of randomization to the date of death from any cause. Overall survival was estimated among participants from the PPS using the Kaplan-Meier approach. The 95% CI for median was computed using the method of Brookmeyer and Crowley.
Query!
Timepoint [2]
0
0
From date of randomization until death or premature withdrawal (up to approximately 31 months or data cutoff date of 13 February 2015)
Query!
Secondary outcome [3]
0
0
Percentage of Participants With Disease Progression or Death - PPS
Query!
Assessment method [3]
0
0
Disease progression was defined by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as a =20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including Baseline (nadir). In addition to the relative increase of 20%, the sum was also required to demonstrate an absolute increase of =5 millimeters (mm). The percentage of participants who died or experienced disease progression as of the analysis data cutoff date of 13 February 2015 was reported among participants from the PPS.
Query!
Timepoint [3]
0
0
From date of randomization until first occurrence of disease progression or death; assessed every 6 weeks (up to approximately 31 months or data cutoff date of 13 February 2015)
Query!
Secondary outcome [4]
0
0
Progression-Free Survival - PPS
Query!
Assessment method [4]
0
0
Progression-free survival was defined as the time between the day of randomization and the date of first documentation of disease progression or date of death, whichever occurred first, measured following RECIST Version 1.1 criteria. Disease progression was defined as a =20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including Baseline (nadir). In addition to the relative increase of 20%, the sum was also required to demonstrate an absolute increase of =5 mm. The 95% CI for median was computed using the method of Brookmeyer and Crowley.
Query!
Timepoint [4]
0
0
From date of randomization until first occurrence of disease progression or death; assessed every 6 weeks (up to approximately 31 months or data cutoff date of 13 February 2015)
Query!
Secondary outcome [5]
0
0
Percentage of Participants With Objective Response - PPS
Query!
Assessment method [5]
0
0
Objective response was defined as the occurrence of either a complete response (CR) or partial response (PR) as determined by RECIST Version 1.1 based on investigator assessment. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) were required to have reduction in short axis to \<10 mm. PR was defined as a =30% decrease in the sum of diameters of target lesions, taking as reference the Baseline sum diameters. The 95% CI was constructed using Blyth-Still-Casella method.
Query!
Timepoint [5]
0
0
From date of randomization until first occurrence of disease progression or death; assessed every 6 weeks (up to approximately 31 months or data cutoff date of 13 February 2015)
Query!
Secondary outcome [6]
0
0
Trastuzumab Cmin on Day 21 of Cycles 1 to 11 - FAS
Query!
Assessment method [6]
0
0
Cmin samples were obtained in all participants randomized to receive Herceptin (FAS). The observed Cmin was recorded, averaged among all participants, and expressed in µg/mL.
Query!
Timepoint [6]
0
0
Day 21 of Cycle 1, 2, 3, 4, 5, 7, 9, 11 (cycle length = 21 days)
Query!
Secondary outcome [7]
0
0
Trastuzumab Serum Concentration on Day 1 of Cycle 1 - FAS
Query!
Assessment method [7]
0
0
Trastuzumab serum concentration samples were obtained in all participants randomized to receive Herceptin (FAS). The observed concentration values were recorded, averaged among all participants, and expressed in µg/mL.
Query!
Timepoint [7]
0
0
Pre-dose (0 minutes) and within 15 minutes after end of 2-hour Herceptin infusion on Day 1 of Cycle 1 (cycle length = 21 days)
Query!
Eligibility
Key inclusion criteria
* Histologically confirmed adenocarcinoma of the stomach or gastro-esophageal junction with metastatic disease documented to involve at least liver or lung or both
* Measurable disease according to RECIST Version 1.1 or non-measurable evaluable disease
* At least 2 organs involved in metastatic gastric tumor (including at least lung or liver or both) in addition to the site of primary tumor, where metastasis in distant lymph nodes, peritoneal metastasis, and malignant pleural effusion may count as "organs" in this context
* HER2-positive primary or metastatic tumor as assessed by central laboratory
* Adequate renal function (creatinine clearance greater than equal to (=) 45 milliliters per minute [mL/min])
* Eastern Cooperative Oncology Group (ECOG) performance status of 2
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Previous chemotherapy for locally advanced or metastatic disease
* Prior gastrectomy (partial or total) for the underlying malignant disease under investigation
* Prior therapy with an anti-HER2 agent and/or platinum-based chemotherapeutic agent
* Residual relevant toxicity resulting from previous therapy
* Lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome (such as jejunostomy probe and gastric or jejunostomy tubes) which may impair the ability to administer or absorb capecitabine
* Current (significant or uncontrolled) gastrointestinal bleeding
* Other malignancy within the last 5 years, except for carcinoma in situ of the cervix and basal or squamous cell carcinoma of the skin
* History of documented congestive heart failure, angina pectoris requiring medication, electrocardiogram (ECG) evidence of transmural myocardial infraction, poorly controlled hypertension, clinically significant valvular heart disease, or high-risk uncontrollable arrhythmias
* Baseline left ventricular ejection fraction (LVEF) less than (<) 50%, documented by echocardiography, multiple-gated radionuclide angiography (MUGA) scan, or cardiac magnetic resonance imaging (MRI)
* Chronic or high-dose corticosteroid therapy
* History or clinical evidence of brain metastases
* Pregnant women
* Active infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C, or HIV-seropositive
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Stopped early
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/12/2011
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/08/2015
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
296
Query!
Recruitment in Australia
Recruitment state(s)
NSW,SA,WA
Query!
Recruitment hospital [1]
0
0
- Port Macquarie
Query!
Recruitment hospital [2]
0
0
- Wahroonga
Query!
Recruitment hospital [3]
0
0
- Woodville South
Query!
Recruitment hospital [4]
0
0
- Murdoch
Query!
Recruitment postcode(s) [1]
0
0
2444 - Port Macquarie
Query!
Recruitment postcode(s) [2]
0
0
2076 - Wahroonga
Query!
Recruitment postcode(s) [3]
0
0
5011 - Woodville South
Query!
Recruitment postcode(s) [4]
0
0
6150 - Murdoch
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Indiana
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Kansas
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
New York
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Oregon
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
South Carolina
Query!
Country [7]
0
0
Bosnia and Herzegovina
Query!
State/province [7]
0
0
Banja Luka
Query!
Country [8]
0
0
Bosnia and Herzegovina
Query!
State/province [8]
0
0
Sarajewo
Query!
Country [9]
0
0
Brazil
Query!
State/province [9]
0
0
RJ
Query!
Country [10]
0
0
Brazil
Query!
State/province [10]
0
0
RS
Query!
Country [11]
0
0
Brazil
Query!
State/province [11]
0
0
SP
Query!
Country [12]
0
0
Chile
Query!
State/province [12]
0
0
Santiago
Query!
Country [13]
0
0
Chile
Query!
State/province [13]
0
0
Viña del Mar
Query!
Country [14]
0
0
China
Query!
State/province [14]
0
0
Beijing
Query!
Country [15]
0
0
China
Query!
State/province [15]
0
0
Changchun
Query!
Country [16]
0
0
China
Query!
State/province [16]
0
0
Changsha
Query!
Country [17]
0
0
China
Query!
State/province [17]
0
0
Changzhou
Query!
Country [18]
0
0
China
Query!
State/province [18]
0
0
Guangzhou
Query!
Country [19]
0
0
China
Query!
State/province [19]
0
0
Hangzhou
Query!
Country [20]
0
0
China
Query!
State/province [20]
0
0
Nanjing
Query!
Country [21]
0
0
China
Query!
State/province [21]
0
0
Shanghai
Query!
Country [22]
0
0
China
Query!
State/province [22]
0
0
Wuhan
Query!
Country [23]
0
0
China
Query!
State/province [23]
0
0
Zhengzhou
Query!
Country [24]
0
0
Czech Republic
Query!
State/province [24]
0
0
Brno
Query!
Country [25]
0
0
Czech Republic
Query!
State/province [25]
0
0
Olomouc
Query!
Country [26]
0
0
Czech Republic
Query!
State/province [26]
0
0
Praha 2
Query!
Country [27]
0
0
Czech Republic
Query!
State/province [27]
0
0
Praha 8
Query!
Country [28]
0
0
Germany
Query!
State/province [28]
0
0
Berlin
Query!
Country [29]
0
0
Germany
Query!
State/province [29]
0
0
Frankfurt
Query!
Country [30]
0
0
Germany
Query!
State/province [30]
0
0
Mannheim
Query!
Country [31]
0
0
Hungary
Query!
State/province [31]
0
0
Budapest
Query!
Country [32]
0
0
Hungary
Query!
State/province [32]
0
0
Pecs
Query!
Country [33]
0
0
Hungary
Query!
State/province [33]
0
0
Szolnok
Query!
Country [34]
0
0
Hungary
Query!
State/province [34]
0
0
Szombathely
Query!
Country [35]
0
0
Hungary
Query!
State/province [35]
0
0
Veszprem
Query!
Country [36]
0
0
Italy
Query!
State/province [36]
0
0
Calabria
Query!
Country [37]
0
0
Italy
Query!
State/province [37]
0
0
Campania
Query!
Country [38]
0
0
Italy
Query!
State/province [38]
0
0
Emilia-Romagna
Query!
Country [39]
0
0
Italy
Query!
State/province [39]
0
0
Friuli-Venezia Giulia
Query!
Country [40]
0
0
Italy
Query!
State/province [40]
0
0
Lombardia
Query!
Country [41]
0
0
Italy
Query!
State/province [41]
0
0
Marche
Query!
Country [42]
0
0
Italy
Query!
State/province [42]
0
0
Toscana
Query!
Country [43]
0
0
Korea, Republic of
Query!
State/province [43]
0
0
Bundang City
Query!
Country [44]
0
0
Korea, Republic of
Query!
State/province [44]
0
0
Incheon
Query!
Country [45]
0
0
Korea, Republic of
Query!
State/province [45]
0
0
Seoul
Query!
Country [46]
0
0
Mexico
Query!
State/province [46]
0
0
Distrito Federal
Query!
Country [47]
0
0
Mexico
Query!
State/province [47]
0
0
Mexico City
Query!
Country [48]
0
0
Mexico
Query!
State/province [48]
0
0
Monterrey
Query!
Country [49]
0
0
Mexico
Query!
State/province [49]
0
0
Oaxaca
Query!
Country [50]
0
0
New Zealand
Query!
State/province [50]
0
0
Auckland
Query!
Country [51]
0
0
Panama
Query!
State/province [51]
0
0
Panama
Query!
Country [52]
0
0
Peru
Query!
State/province [52]
0
0
Arequipa
Query!
Country [53]
0
0
Peru
Query!
State/province [53]
0
0
Lima
Query!
Country [54]
0
0
Peru
Query!
State/province [54]
0
0
Trujillo
Query!
Country [55]
0
0
Philippines
Query!
State/province [55]
0
0
Manila
Query!
Country [56]
0
0
Philippines
Query!
State/province [56]
0
0
Pasig City
Query!
Country [57]
0
0
Poland
Query!
State/province [57]
0
0
Krakow
Query!
Country [58]
0
0
Poland
Query!
State/province [58]
0
0
Lublin
Query!
Country [59]
0
0
Poland
Query!
State/province [59]
0
0
Warsaw
Query!
Country [60]
0
0
Poland
Query!
State/province [60]
0
0
Wieliszew
Query!
Country [61]
0
0
Portugal
Query!
State/province [61]
0
0
Porto
Query!
Country [62]
0
0
Russian Federation
Query!
State/province [62]
0
0
Ivanovo
Query!
Country [63]
0
0
Russian Federation
Query!
State/province [63]
0
0
Omsk
Query!
Country [64]
0
0
Russian Federation
Query!
State/province [64]
0
0
Ryazan
Query!
Country [65]
0
0
Russian Federation
Query!
State/province [65]
0
0
St Petersburg
Query!
Country [66]
0
0
Russian Federation
Query!
State/province [66]
0
0
Stavropol
Query!
Country [67]
0
0
Russian Federation
Query!
State/province [67]
0
0
Tula
Query!
Country [68]
0
0
Serbia
Query!
State/province [68]
0
0
Belgrade
Query!
Country [69]
0
0
Serbia
Query!
State/province [69]
0
0
Nis
Query!
Country [70]
0
0
Serbia
Query!
State/province [70]
0
0
Sremska Kamenica
Query!
Country [71]
0
0
South Africa
Query!
State/province [71]
0
0
Bloemfontein
Query!
Country [72]
0
0
South Africa
Query!
State/province [72]
0
0
Cape Town
Query!
Country [73]
0
0
South Africa
Query!
State/province [73]
0
0
Johannesburg
Query!
Country [74]
0
0
Spain
Query!
State/province [74]
0
0
Barcelona
Query!
Country [75]
0
0
Spain
Query!
State/province [75]
0
0
Madrid
Query!
Country [76]
0
0
Turkey
Query!
State/province [76]
0
0
Adana
Query!
Country [77]
0
0
Turkey
Query!
State/province [77]
0
0
Gaziantep
Query!
Country [78]
0
0
Turkey
Query!
State/province [78]
0
0
Istanbul
Query!
Country [79]
0
0
Turkey
Query!
State/province [79]
0
0
Izmir
Query!
Country [80]
0
0
Turkey
Query!
State/province [80]
0
0
Malatya
Query!
Country [81]
0
0
Turkey
Query!
State/province [81]
0
0
Sihhiye, ANKARA
Query!
Country [82]
0
0
Ukraine
Query!
State/province [82]
0
0
Cherkassy
Query!
Country [83]
0
0
Ukraine
Query!
State/province [83]
0
0
Chernivtsi
Query!
Country [84]
0
0
Ukraine
Query!
State/province [84]
0
0
Dnipropetrovsk
Query!
Country [85]
0
0
Ukraine
Query!
State/province [85]
0
0
Donetsk
Query!
Country [86]
0
0
Ukraine
Query!
State/province [86]
0
0
Kiev
Query!
Country [87]
0
0
Ukraine
Query!
State/province [87]
0
0
Lvov
Query!
Country [88]
0
0
United Kingdom
Query!
State/province [88]
0
0
Denbighshire
Query!
Country [89]
0
0
United Kingdom
Query!
State/province [89]
0
0
Leicester
Query!
Country [90]
0
0
United Kingdom
Query!
State/province [90]
0
0
Southampton
Query!
Country [91]
0
0
United Kingdom
Query!
State/province [91]
0
0
Wolverhampton
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Hoffmann-La Roche
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This randomized, open-label, multicenter, international Phase IIIb study will compare the efficacy and safety of two Herceptin dosing regimens in combination with cisplatin/capecitabine chemotherapy in participants with HER2-positive metastatic gastric or gastro-esophageal junction adenocarcinoma. Participants who have not received prior treatment for metastatic disease will be randomized to receive Herceptin intravenously as either an 8-milligram per kilogram (mg/kg) loading dose followed by 6 mg/kg every 3 weeks (q3w) as standard of care or an 8-mg/kg loading dose followed by 10 mg/kg q3w until disease progression. Capecitabine will be administered for 6 cycles at a dose of 800 milligrams per meter-squared (mg/m\^2) orally twice a day on Days 1 to 14 of each 3-week cycle, and cisplatin will be administered intravenously for 6 cycles at a dose of 80 mg/m\^2 on Day 1 of each 3-week cycle. Herceptin will be continued until disease progression occurs.
Query!
Trial website
https://clinicaltrials.gov/study/NCT01450696
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Trials
Query!
Address
0
0
Hoffmann-La Roche
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT01450696
Download to PDF